FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

Another Rock Island County Sheriff’s Office deputy said he intends to run for sheriff in 2026. Timothy Gillette, a 28-year ...

Despite the many warnings by law enforcement — reinforced by this newspaper — to be wary of anyone purporting to act in your best interests, egregious examples of violations of that trust continue ...

Around 5:30 p.m., troopers were sent to a report of a single motorcycle crash where Megan Bouchard, 25, the rider, was on a ...

After delaying a June PDUFA date, the U.S. FDA has approved Kalvista Pharmaceuticals Inc.’s Ekterly (sebetralstat) for hereditary angioedema (HAE) in those aged 12 and older. The plasma kallikrein ...

The U.S. Food and Drug Administration (FDA) has upgraded a recall of tomatoes sold in three southern states to a Class I recall, the most serious level, because the tomatoes may be contaminated ...

The implied impact of Medicare drug coverage improvement on drug utilization by the elderly is about 6 percent (0.4 × 14 percent).

Exhibit 2 shows monthly data on the amount paid by the patient per day of therapy, by age group. From September 2004 to December 2005, the amounts paid by elderly and nonelderly patients per day ...

Colorado health providers cheer the approval but say the drug costs $14,000 per shot. Yeztugo is the first and only injectable HIV prevention medication.